Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) [Seeking Alpha]
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know [Yahoo! Finance]
Organon Reports Results for the Third Quarter Ended September 30, 2024
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)